Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases

Kathryn E. Blethen, Tasneem A. Arsiwala, Ross A. Fladeland, Samuel A. Sprowls, Dhruvi M. Panchal, Chris E. Adkins, Brooke N. Kielkowski, Leland E. Earp, Morgan J. Glass, Trenton A. Pritt, Yssabela M. Cabuyao, Sonikpreet Aulakh, and Paul R. Lockman

Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, West Virginia, USA (K.E.B., T.A.A., R.A.F., S.A.S., D.M.P., B.N.K., M.J.G., T.A.P., Y.M.C., P.R.L.); Department of Chemical and Biomedical Engineering, Benjamin M. Statler College of Engineering and Mineral Resources, West Virginia University, Morgantown, West Virginia, USA (D.M.P.); Department of Cancer Cell Biology, School of Medicine, West Virginia University, Morgantown, West Virginia, USA (L.E.E., S.A.); Department of Pharmaceutical Sciences, School of Pharmacy, South University, Savannah, Georgia, USA (C.E.A.)

Corresponding Author: Paul R. Lockman, PhD, Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, 108 Biomedical Drive, Morgantown, WV 26506, USA (prlockman@hsc.wvu.edu).

Abstract

The blood-brain barrier is the selectively permeable vasculature of the brain vital for maintaining homeostasis and neurological function. Low permeability is beneficial in the presence of toxins and pathogens in the blood. However, in the presence of metastatic brain tumors, it is a challenge for drug delivery. Although the blood-tumor barrier is slightly leaky, it still is not permissive enough to allow the accumulation of therapeutic drug concentrations in brain metastases. Herein, we discuss the differences between primary brain tumors and metastatic brain tumors vasculature, effects of therapeutics on the blood-tumor barrier, and characteristics to be manipulated for more effective drug delivery.

Keywords

blood-brain barrier | brain metastases | breast cancer | drug delivery

Blood-Brain Barrier (BBB) and Blood-Tumor Barrier (BTB)

The BBB is comprised of a neurovascular unit (NVU) consisting of capillary endothelial cells, pericytes, astrocytes, and a basement membrane.1 The innermost layer of the BBB is formed by endothelial cells which establish a barrier between circulating blood and the brain parenchyma.2 A basement membrane of extracellular matrix and pericytes envelops the endothelial cells to support structural integrity.3 Astrocytic end feet are located along the outermost layer of the NVU and play a significant role in regulatory processes such as K+ buffering, brain pH, and other metabolic processes.4 Interactions between these cells and their microenvironment are vital to maintain BBB integrity and brain homeostasis. However, when cancer cells displace endothelia from the other NVU cells the BBB breaks down and solute movement whether passive or actively transported is altered. It is important to note most of what is known about the BBB and BTB is due to preclinical work in mouse models.

Brain Metastases vs Glioblastoma

The BTB restricts chemotherapeutic efficacy and contributes to tumor progression in both primary and metastatic brain tumors. Glioblastoma (GBM) is the most common, malignant primary brain tumor characterized often by a hypoxic necrotic center and invasive growth into normal brain tissue.5 Disruption of the BBB by invasive GBM was long considered uniformly leaky but is now understood to have a nonuniform,
heterogeneous microvasculature composition with increasing distance from the tumor core. In early states, that is, low-grade glioma, the BBB remains nominally intact and little disruption is present as the tumor relies on the normal brain microvasculature. However, this changes dramatically as the tumor grows and progresses into a higher grade glioma where tumor cells, through a variety of molecular signals, drive the separation of endothelial tight junctions, dissociation of astrocytic processes, and recruitment of differential pericyte populations. Malignant GBM cells are also highly migratory and remodel the extravascular basement membrane through release of several soluble factors and induction of a cascade of pro-tumorigenic pathways. These properties help promote chemotherapeutic and radiation therapy resistance as the leading edge of the tumor continues to expand and co-opt existing brain capillaries.

In contrast to the development of GBM, metastatic brain tumors arise from a peripheral primary tumor location. The most common cancer types contributing to the formation of brain metastases are lung, breast, and melanoma. Initial steps of lesion formation are similar to immune cell trans-endothelial migration, which include tethering, rolling, adhesion, and diapedesis. Extravasating into the brain parenchyma beyond the endothelia level has been observed to take longer than in other organs ranging between 2 and 14 days depending upon primary tumor type. As the metastatic cells continue to grow beyond the BBB, nutrient and oxygen demand increase leading to vascular co-option, a process by which tumor cells alter the existing brain microvasculature. Simultaneously, angiogenesis occurs to provide cancer cells with nutrients to support proliferation and survival. The immature vessels formed during this process are fenestrated and lack endothelial tight junction protein complexes allowing increased vascular permeability. These immature capillaries are “leaky” compared to normal BBB capillaries. While the lesion continues to grow in size, the tumor becomes more hypoxic and secretes vascular endothelial growth factor (VEGF) to induce more angiogenesis. This dynamic process contributes to BTB permeability. Interestingly, no correlation has been observed between lesion size and vascular permeability in preclinical brain metastasis models. Clinically, substantial intra- and inter-tumoral heterogeneity exists among brain metastases in the same brain. Differences between the BBB and BTB are shown in Figure 1.

Heterogeneity of Blood-Tumor Barrier in Brain Metastases

There are relatively few studies comparing the vascular permeability of metastatic brain lesions (regardless of type) to a primary tumor. The data presented are often difficult to reconcile due to varying methods clinically available and disparities in how a given method is conducted. For example, in comparing data between CT perfusion studies for astrocytomas and GBM vs central metastatic lesions from lung, breast, and melanoma the permeability values for astrocytomas and GBM vs central metastatic lesions are often different. In comparing data between CT perfusion studies for astrocytomas and GBM vs central metastatic lesions from lung, breast, and melanoma the permeability values are often different. However, these studies were a compilation of several lesion types, which could be driven by the vascular density of the lesions.

The BTB is anatomically different in brain metastases of breast cancer compared to a primary CNS tumor, which

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Differences between the BBB and BTB. (A) Endothelial cells in a healthy brain are held together by tight junction proteins and prevent paracellular transport. The endothelial cells are surrounded by a basement membrane embedded with pericytes and astrocytic foot processes along the outside. (B) The BTB is leakier than the BBB due to lack of tight junction proteins and decreased association of astrocytic end-foot processes and pericytes with the barrier.
We have observed quantifiable permeability increases, albeit sometimes subtle, in nearly every metastatic brain lesion. It should be noted for us to quantify the slight permeability increases, we use quantitative multimodal fluoroscopic and laser phosphorescent autoradiography to detect spatial permeability changes at a 1-micron resolution and drug tissue concentrations of 1 femtogram. This technique was adapted from prior double or triple autoradiography techniques and is well suited to study preclinical metastases since it has <1-µm resolution and with 14C-phosphorescence, tracer distribution can be mapped in 10-µm pixels at levels (~0.3 nCi/g). The variability in permeability has significant implications for the effective delivery of chemotherapeutics within and between lesions in the same brain.

Despite the breakdown of the BBB in brain metastases of breast cancer, it still significantly restricts drug delivery and inhibits cytotoxicity in ~90% of CNS metastases. The poor delivery of chemotherapy within the brain lesion provides a sanctuary for the lesion to progress, in the presence of sub-therapeutic chemotherapy concentrations, within the brain microenvironment. Many chemotherapeutics exhibit restricted distribution because permeability increases are inadequate and or they are removed by efflux transporters that remain highly active despite the breakdown of the vasculature. This phenomenon we have observed for paclitaxel and doxorubicin as well as trastuzumab, lapatinib, and vorinostat.

**Drug Delivery for Brain Metastases**

Although many successful compounds have shown effectiveness in treating peripheral tumors with targeted agents, the same cannot be said for treating brain tumors. This lack of success may be due to inadequate delivery of otherwise effective compounds. Many factors affect how these drugs are delivered to the brain, but one major challenge is a heterogeneously leaky BTB. Future success of brain cancer therapeutics depends on the delivery of active drugs to the target at efficacious concentrations, which may include combinations of targeted drugs tailored to each patient's tumor type.

Traditional cytotoxic therapeutics have played a limited role in the treatment of brain metastases. The distribution of systemically administered chemotherapies is hampered by the BTB, which is frequently disrupted in patients with brain metastases. We analyzed over 2000 brain metastases in different preclinical models of metastatic breast cancer (human 231-BR-HER2 and murine 4T1-BR5) and found in over 89% of lesions, there was a partial compromise in BTB permeability. Nevertheless, the concentration of drugs only reached lethal levels in a small fraction (10%) of the most permeable metastases. Several trials evaluating the use of systemic drugs in patients with brain metastases have failed to demonstrate notable response rates, including cisplatin and pemetrexed, cisplatin and vinorelbine, paclitaxel and cisplatin, and temozolomide.

Targeted therapies utilized to treat brain metastases have minimal brain distribution. Only 5% administered dose of Trastuzumab, which targets HER2+ breast cancer, is found in the brain.
in brain lesions in preclinical mouse models. Clinically, the ratio of trastuzumab in serum to cerebrospinal fluid is 420:1. Often a factor limiting drug delivery to brain metastases is the high degree of expression of ABC efflux transporters at the BBB and BTB. In preclinical studies, there is strong evidence for the interaction of vemurafenib, dabrafenib, trametinib, palbociclib, cobimetinib, doxorubicin, and paclitaxel being effluxed by P-gp (P-glycoprotein) and BCRP (breast cancer resistance protein). The brain concentrations achieved by most of these drugs are less than 10% of their plasma concentrations (Table 1). Moreover, the multidrug resistance protein 1 (MRP1) receptor acts by promoting drug resistance along with active efflux of drugs. This provides an additional challenge to achieving optimal drug concentrations across the BTB.

**Immunotherapy for Brain Metastases**

Although the CNS was once considered immune-privileged, studies have shown immune cells, specifically T cells, cross the BBB to perform immune surveillance. Brain metastases are now being researched as possible targets for a variety of immunotherapies, such as checkpoint inhibitors and adoptive cell therapy (ACT). The benefit of immunotherapy is immunosuppression without the toxicity associated with chemotherapeutic agents. However, the microenvironment of solid tumors can evade immune responses by impeding the infiltration of immune cells into the tumor, contributing to the variability in responses seen among patients.

Checkpoint protein receptors, such as CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) and PD-1 (programmed death 1), are expressed on T cells. These checkpoints block immune responses and allow the tumor cells to evade the immune system. When checkpoints are inhibited, T cells are activated by the primary tumor and kill the cancer cells. Examples of immune checkpoint inhibitors are ipilimumab, which blocks CTLA-4, and pembrolizumab and nivolumab, which block the ligand PD-L1. Checkpoint immunotherapy is in clinical trials for patients with brain tumors, including advanced metastases and GBM. A 2010 study of individuals initially treated for metastatic melanoma which allowed enrollment of patients with treated CNS metastases was the first study to establish ipilimumab treatment improved survival. In addition, pembrolizumab and nivolumab have been clinically assessed for efficacy in patients with melanoma and lung cancer brain metastasis. Increased PD-L1 and CTLA-4 expression are indicative of therapeutic efficacy. In a study of patients with melanoma brain metastases, patients with tumor PD-L1 expression of 5% or more had a higher chance of benefiting from combination therapy (nivolumab and ipilimumab) than those with <5% tumor PD-L1 expression.

Some issues have arisen as a result of the increased use of checkpoint inhibitors. Tumor inflammation and pseudoprogression, which are often seen on imaging, may cause additional symptoms and make tumor growth assessment difficult. The ability to successfully target brain metastases only among certain patients, such as those expressing high levels of PD-L1, may be a potential limitation of checkpoint inhibitors. These limitations are significant in some patients to the degree that they may have little to no benefit from the currently available checkpoint inhibition therapies. The efficacy of immune checkpoint inhibitors on brain metastases is dependent on the ability of T cells to become activated by the primary tumor, cross the BBB and/or BTB, and attack tumor cells in the brain. Most of the data reported for checkpoint inhibitors in brain metastases have combinatorial therapy with other immunotherapeutic agents, radiation, chemotherapeutic agents, or neurosurgery. Additional studies are necessary to explore these challenges and determine how to successfully target tumor cells in the brain.

ACT is a procedure that involves the transfer of autologous immune cells to a recipient to induce an antineoplastic effect. Cells from the primary tumor site or peripheral metastases are cultured in vitro with cytokines and lymphocytes. The immune cells are expanded and

---

**Table 1. Brain-to-Plasma Ratio of Various P-gp and BCRP Substrate Chemotherapeutic Agents for the Treatment of Brain Metastases**

| Chemotherapeutic Agent | Cancer Type | Molecular Target | Clinical Status | Substrate P-gp | BCRP | Brain-to-Plasma Ratio | Reference |
|------------------------|-------------|------------------|----------------|----------------|------|-----------------------|-----------|
| Vemurafenib            | Melanoma    | Mutant BRAF      | Approved       | Yes            | Yes  | 1.00 ± 0.19           | 112, 113  |
| Dabrafenib             | Melanoma, non–small-cell lung cancer, and thyroid cancer | Mutant BRAF | Approved | Yes | Yes | 0.25 | 114 |
| Trametinib             | Melanoma, non–small-cell lung cancer, and thyroid cancer | MEK | Approved | Yes | No | 2.45 ± 1.3 | 115 |
| Cobimetinib            | Melanoma    | MEK              | Approved       | Yes            | No   | 1.1, 6.2              | 116       |
| Palbociclib            | Breast cancer | CDK4/6          | Approved       | Yes            | Yes  | 28 ± 6                | 117       |
| Doxorubicin            | Breast cancer, leukemia, lymphoma, ovarian cancer, neuroblastoma, bone cancer, and thyroid cancer | Topoisomerase II | Approved | Yes | Yes | 0.0014 | 118 |
| Paclitaxel             | Breast cancer, lung cancer, ovarian cancer, and Kaposi's sarcoma | Tubulin beta-1 chain, apoptosis regulator Bcl-2 | Approved | Yes | No | <3% | 17,106 |

---

Downloaded from https://academic.oup.com/noa/article/3/Supplement_5/v136/6444211 by guest on 04 December 2021
**Modulation of BBB Permeability**

Bevacizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody that binds to VEGF to decrease endothelial proliferation and formation of new blood vessels.\(^6\) Bevacizumab in primary brain cancer, such as GBM, is well known to improve progression-free survival when used alone and/or in combination with chemotherapeutic agents.\(^6\) The objective of bevacizumab is to normalize the vasculature of the tumor and improve oxygenation to aid in delivery of anti-cancer drugs. Bevacizumab also contributes to normalization of the blood vessels in the tumor with low permeability, hence leading to decreased penetration of drugs. Additionally, these tumors would become more invasive by co-opting normal blood vessels.\(^7\) Preclinical studies suggest long-term use of bevacizumab leads to decrease in BBB permeability.\(^7\)

Recently, bevacizumab has been studied in combination with radiation therapy. The REBECA trial was the first clinical trial to study the effects of bevacizumab and whole-brain radiation therapy in patients with brain metastases. Results demonstrated a synergistic effect between the 2 treatment modalities.\(^7\) One study combining bevacizumab with stereotactic radiosurgery improved treatment efficacy and reduced edema in a study of patients with lung cancer brain metastases.\(^7\) Clinical studies in GBM patients show increased progression-free survival in phase II and III trials, but little to no change in overall survival.\(^7\) Bevacizumab is more efficacious as a preventative treatment for brain tissue necrosis than as a tumor treatment with radiotherapy.\(^7\)

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases with the primary function to degrade extracellular matrix. These MMPs have role in breast cancer initiation, growth, angiogenesis as well as activation of growth factors. Currently, MMP inhibitors are being studied to evaluate their efficacy in breast cancer. While the use of MMP inhibitors in several brain diseases such as intracerebral hemorrhage, cerebral ischemia, and cold injury has shown to decrease the BBB permeability, there is no concrete evidence to support its efficacy with brain tumors. Studies show MMPs contribute to tumor cells entering and exiting the vasculature to seed in metastatic sites throughout the body. Although results are inconclusive if MMP inhibitors can treat brain metastases, they could potentially prevent metastatic malignant cells invasion.\(^7\)

The role of MMP and its inhibitors may be investigated further in brain metastases.\(^7\)

Aquaporins (AQP) regulate intra-/extracellular water balance by transportation of fluid across the plasma membranes. Among 13 subtypes of AQP, AQP4 is most abundantly present in the brain and is responsible for cytotoxic edema. Since AQP inhibitors including cryoablation have been in use for the clinical management of breast cancer, inhibition of AQP may be used as an adjunct treatment to lower the BBB permeability.\(^7\)

Dexamethasone is a corticosteroid with anti-inflammatory effects and low mineralocorticoid activity. Among several roles in cancer management, dexamethasone is widely used in controlling pain, nausea, and fatigue. Clinical and preclinical reports suggest dexamethasone can dramatically decrease the BBB/BTB permeability as well as regional vascular tight junction structure.\(^9\)

**Treatments to Increase BBB Permeability**

Lack of BBB permeation of therapeutics has fueled research into techniques to increase BBB permeability to
increase distribution of drugs into brain and tumor lesions. MRI-guided focused ultrasound is a relatively newer technique for BBB/BTB disruption. The delivery of focused ultrasound at higher energies is able to ablize a tumor mass within the brain [high-intensity focused ultrasound (HIFU)]. However, at lower energies in the presence of vascular gas-filled microbubbles (low-intensity focused ultrasound [LIFU]) the LIFU causes a BBB opening.

The LIFU medicated increase in BBB permeability occurs by a combination of physical effects on the NVU and secondary inflammatory responses. Under the exposure of focused ultrasound, microbubbles undergo oscillations within the vasculature impacting the endothelial cell membrane. The exerted pressure of the microbubble against spaces between endothelia transiently increases the aqueous diffusion of drugs into the brain. The secondary effect of acoustic cavitations includes sterile inflammation. After LIFU, there is a release and elevation of heat-shock protein 70, IL-8, TNF-α, and damage-associated molecular patterns in the parenchyma. Aravantis et al examined the effect of focused ultrasound with the uptake of 2 relevant chemotherapies, doxorubicin and ado-trastuzumab emtansine in a HER2 amplified estrogen-dependent model of breast cancer brain metastasis. They observed a 7-fold increase in doxorubicin brain uptake and 2-fold increase in the antibody-drug conjugate. Similarly, trastuzumab plus LIFU increased median survival and reduced tumor volume as compared to non-treated group in a Her2 and neo positive model of brain metastasis of breast cancer. Despite evidence of preclinical success, LIFU parameters such as including power, cavitation dose, and duration of sonications needs to be elucidated to achieve consistent and reliable BBB/BTB opening in clinical studies.

While radiation remains the standard of care treatment therapy for most brain malignancies, it has been shown that low doses of radiotherapy may enhance BTB permeability to chemotherapy. For example, early work demonstrated that CNS irradiation of 60Gy caused BBB and BTB leakage of horseradish peroxidase, loss of capillary networks, white matter necrosis, and cortical atrophy. These effects were ameliorated 6- to 12-week post-radiation injury. Later work demonstrated effects were dose-dependent and fractionated doses up to 20-30 Gy increased BBB permeability without producing acute or chronic side effects.

Increased permeability following radiotherapy occurs by a primary physiological effect on the brain endothelium followed by a secondary neuroinflammatory response. The inflammatory response may be through an extracranial abscopal effect where radiation damage at the endothelium causes a release of tumor-associated antigens. Direct effects of radiation include a decrease in tight junction protein expression, decreased endothelial cell density, endothelial apoptosis, and higher transcellular transport. Acute effects post-radiotherapy are initiated by inflammatory mediators like activated astrocytes and microglia, TNF-α, IL-6, ICAM-1, and IL-1β.

Reports regarding the extent and time course of radiation-mediated BBB/BTB opening are not consistent. A study by Yuan and colleagues evaluating the effects of fractionated radiotherapy (2Gy, 5 days a week) on brain microvasculature showed BBB permeability did not increase until 90-day post-irradiation. They found higher vesicular activity, lower tight junction density, and increased number of astrocytes in the brain between 90- and 180-day post-irradiation. However, a separate study found acute increase in BBB permeability 24-48 hours post-radiation after a 20Gy radiation dose. Interestingly, the radiation-induced increase in microvascular network could be rescued by anti-TNF treatment. A 2016 preclinical study investigated the effects of radiotherapy on tumor burden and permeability in a breast cancer brain metastasis model. The study demonstrated clinically relevant doses of whole-brain radiation of 20Gy fractions reduced tumor volumes of enhancing tumors but non-enhancing impermeable tumors.

Physical disruption of the BBB can also be carried out by the infusion of a hyperosmotic solution of mannitol (25% w/v) or arabinose into the internal carotid artery. Change in osmolarity of the cerebrovascular endothelial cells causes dilation and shrinkage of the vasculature, leading to an increase in the inter-endothelial space. Widening between the tight junctions (approx. 200 Å) and contraction of endothelial cytoskeleton by calcium causes increase in the BBB permeability, which is highly transient and can last from a few minutes to a few hours. In addition to higher bulk flow rates, there may also be secondary neuroinflammatory responses with osmotic opening. Higher brain levels of cytokines, trophic factors, damage-associated molecular patterns, and cell adhesion molecules have been observed to occur 5-minute post-infusion. Moreover, sterile inflammatory responses were also observed in the contralateral hemispheres. Neuroinflammatory processes returned back to baseline 96-hour post-osmotic disruption.

While this technique has been extensively explored in primary brain malignancies, its effect on brain metastasis remains unknown. The ability of osmotic disruption to improve delivery of temozolomide was tested in an MGMT-negative lung cancer brain metastasis model. The study revealed BTB disruption enhanced temozolomide delivery within tumors by approximately 3-fold as compared to healthy brain. However, it is important to note BBB disruption with temozolomide was highly toxic and the study group was terminated.

An alternate approach to increase BBB permeability is exploiting the activation of endothelial receptors through natural ligands or their analogs. Biochemical activation of receptors like the adenosine 2A, bradykinin type 2 (B2), calcium-activated potassium channels, or ATP-sensitive potassium channels can increase endocytosis as well as downstream signaling to increase BBB permeation. The effect of bradykinin-induced BBB permeability is dose-dependent, transient, and reversible. A proposed mechanism for bradykinin-induced BBB breakdown involves increase in trans-endothelial transport by pinocytic vesicles, as animals that were pretreated with imidazole, trifluoperazine or indomethacin had a decreased effect. Endogenous peptides, like bradykinin, increase intracellular cytoplasmic Ca2+ levels mediated by endothelial connexin hemichannels. Alternate downstream events include release of free radical oxygen species and arachidonic acid, activation of phospholipase A2, and higher production of IL-1β.
While preclinical studies have promising data, clinical translation has been difficult. First, biochemical modulation of the BBB with bradykinin requires administration of high concentrations of the endogenous ligand, which can cause severe damage to the brain microvasculature. Secondly, bradykinin has a short half-life and very potent metabolites with vasoactive action. This limits the ability of widespread use of bradykinin in the clinic. While selective B2 agonists like labradimil can potentially reduce some the nonspecific side effects, it is yet to be effectively used within the clinic.

In the past decade, laser interstitial thermal therapy (LITT) was developed for treatment of gliomas. Recent evidence suggests this procedure disrupts the BBB.\(^92\) LITT is a minimally invasive ablative technique that induces cell death of cancerous cells while simultaneously disrupting the BBB for several weeks.\(^93,94\) The mechanism behind the novel technique is based on the principle cancer cells are more sensitive to thermal damage than healthy cells. The therapeutic window of LITT, however, is small because tumor cells are damaged at 42°C while normal neurons are damaged at 43°C.\(^92\)

**Manipulation of BBB Receptors to Enter the Brain**

Drugs or drug delivery systems can be designed to take advantage of the unique BTB in brain metastases. For example, the “trojan horse” method transports drugs across the BBB by attaching an antibody or peptide to a drug/nanoparticle to target receptors along the BBB which facilitate receptor transcytosis. Some of the most common receptors used for this purpose in different brain pathologies are transferrin receptor (TfR), insulin receptor (InsR), and LDL-related protein type 1 (LRP1).\(^95\)

TfRs are expressed on the luminal side of the BBB. The TfR uses receptor-mediated transcytosis to bind transferrin, an iron sequestering peptide, and shuttle iron into the brain. Using this approach, docetaxel-loaded micelles conjugated to transferrin had a 20.8-fold increase in comparison to free docetaxel.\(^96\) A few in vivo studies have been performed targeting TfR with brain metastasis animal models and show positive results of increased drug uptake in the brain.\(^97,98\) A study by Wyatt et al assessed the permeability of transferrin-targeted nanoparticles in 3 different models of brain tumors: intracranial, intracarcinoid, and intravenous (tail vein). They observed different levels of uptake in the models. The intravenous model was the least permeable to their nanoparticles, followed by the intracranial model, with the intracarcinoid model being the most permeable.\(^99\) These data highlight the importance of utilizing translationally relevant animal models when evaluating drug delivery to the brain.

A lipid transporter (LRP1 [low-density lipoprotein receptor-related protein 1]) at the BBB binds to LDL and allows lipoproteins to be transcytosed across endothelial cells.\(^100\) One study utilizing an in vivo model of brain metastases showed upregulation of LRP1 increased transcytosis of nanoparticles loaded with doxorubicin and increased survival of mice bearing brain metastases.\(^101\) Whereas a preclinical glioma model demonstrated increased brain uptake and survival with angiopep-2 peptide (ligand for LRP1) conjugated to paclitaxel.\(^102\) More studies are necessary to determine if LRP1 targeted drugs could be efficacious in clinical trials.

Large amino acid transporter 1 (LAT1) transports neutral L-amino acids across the BBB. It is overexpressed in GBM and studies using LAT1 targeting liposomes showed increased brain uptake in glioma models.\(^103\) One study observed a 60% increase in survival with LAT1 liposomes loaded with a STAT3 inhibitor, WP1066.\(^104\) The other study noted their LAT1 liposomes loaded with docetaxel were more cytotoxic in the gliomas of their animal model than docetaxel alone.\(^105\)

Another mechanism of manipulating the BBB to deliver drugs to the brain is by inhibition of efflux transporters, which in theory should allow more influx of chemotherapeutic drugs across the BBB and/or BTB. A study in 2019 measured the uptake of radiolabeled erlotinib in the brains of mice after administration of other P-gp/BCRP substrates. There were significant increases in brain uptake of erlotinib, despite complete inhibition of P-gp and BCRP not being achieved. The most promising inhibitor, tariquidar, increased uptake of erlotinib by 69%.\(^105\) Similarly, animals pretreated with valsapar, a P-gp inhibitor, had increased uptake of paclitaxel by almost 10-fold into the brain and resulted in decreased tumor burden.\(^106\) Sorafenib, a tyrosine kinase inhibitor, in the presence of elacridar, predominantly a BCRP inhibitor, increased the brain-to-plasma ratio by 5-fold.\(^107\) Although these inhibitors were effective increasing drug concentrations delivered to the brain, none have significantly increased patient survival in clinical trials.\(^108\)

A clinical study with healthy male patients observed enhanced brain uptake of radiolabeled erlotinib when an oral dose of erlotinib was administered first. The study also investigated the effects of tariquidar administration on erlotinib brain uptake. Tariquidar was not as effective in increasing radiolabeled erlotinib brain concentrations as pre-administration of erlotinib. This is hypothesized to occur due to saturation of the P-gp and BCRP efflux transporters. Although it is important to note the dosage of erlotinib used was much higher than traditionally recommended and has potentially toxic side effects.\(^109\)

**Conclusion**

The BTB remains a hurdle in the treatment of CNS tumors. This is notably observed when therapeutics are effective in treating peripheral disease, yet treatment of CNS lesions is largely unsuccessful with the same therapy, presumably because of limited drug penetration in the central lesion. Currently, in the clinic, mechanisms to alter the BTB of brain metastases specifically and increase drug uptake are unavailable. The typical regimen is to use therapeutics already designed to penetrate the BTB with 60%-80% bioavailability along with use of radiotherapy. Many techniques have been developed to improve drug delivery to the brain. LiFU shows efficacy in increasing BBB permeability and delivering drug, but more studies are needed to determine optimal treatment strategies. Exploitation of transporters at the BBB for drug delivery are promising...
techniques to increase brain uptake; however, this methodology remains nascent in the clinic.

In the future, it may be beneficial to use BTB molecular differences to target treatment of brain metastases. Ongoing studies of molecular markers of the BTB show differences in pericyte populations, basement membrane formation, and astrocyte attachment to the vessels. One study evaluated vasculature growth patterns of lung, colon, and breast cancer brain metastases from patients. Lung and colon brain metastases had fewer vessels and collagen accumulation in the brain parenchyma, while breast cancer brain metastases had more vessels with collagen accumulation in the tumor core. The vessels also had increased collagen along the walls, increased density and diameter of vessels, added layers of PDGF-β+ pericytes, and detachment of astrocytes. A preclinical study observed dilated capillaries with increased CD31 expression and desmin+ pericytes in a lung cancer brain metastasis model. The study noted a 12-fold decrease in AQP4 along the BTB, which correlates with patient samples. Additional research is necessary to determine molecular disparities between the BBB and BTB for this to be an effective therapeutic target.

Most preclinical works focused on modulation of the BBB to enhance drug delivery have been done in GBM models. It is important to consider the differences in the permeability of the BTB between GBM and brain metastases when developing treatment strategies. While not perfect, numerous intracranial tumor implantation models can mimic the BTB of central tumors, similarly, intracardiac mouse models produce a BTB that has similar heterogeneity of breakdown as clinical brain metastases. Although some preclinical studies show increased penetrance of drugs, this does not always correlate to decreased tumor burden and increased survival, since concentrations generally are sub-therapeutic. Penetration, accumulation, and final central lesion concentration of chemotherapeutics are critical for successful clinical trials.

References

1. Sharif Y, Junmah F, Coplan L, Krosser A, Sharif K, Tubbs RS. Blood brain barrier: a review of its anatomy and physiology in health and disease. Clin Anat. 2018;31(6):812–823.
2. Abbott NJ, Patacchini AA, Dolman DE, Yusof S, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13–25.
3. Thomsen MS, Routhe LJ, Moos T. The vascular basement membrane in the healthy and pathological brain. J Cereb Blood Flow Metab. 2017;37(10):3300–3317.
4. Cabezas R, Avila M, Gonzalez J, et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease. Front Cell Neurosci. 2014;8:211.
5. Grossman SA, Ye X, Piantadosi S, et al.; NABTT CNS Consortium. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16(8):2443–2449.
6. Griffith JI, Rath S, Zhang W, et al. Addressing BBB heterogeneity: a new paradigm for drug delivery to brain tumors. Pharmaceuticals. 2020;12(12):1205.
7. Kane JR. The role of brain vasculature in glioblastoma. Mol Neurobiol. 2019;56(9):6645–6653.
8. Watkins S, Robel S, Kimbrough IF, Robert SM, Ellis-Davies G, Sontheimer H. Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells. Nat Commun. 2014;5:4196.
9. Infanger DW, Cho Y, Lopez BS, et al. Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Cancer Res. 2013;73(23):7079–7089.
10. Pietras A, Katz AM, Ekström EJ, et al. Osteopontin-CD44 signaling in the glioma perivascular niche promotes aggressive tumor growth. Cell Stem Cell. 2014;14(3):357–369.
11. Nayak L, Lee EO, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48–54.
12. Zavyalova MV, Denisov EV, Tashireva LA, et al. Intravasation as a key step in cancer metastasis. Biochemistry (Mosc). 2019;84(7):762–772.
13. Paku S, Döme B, Töth R, Timár J. Organ-specificity of the extravasation process: an ultrastructural study. Cell Exp Metastasis. 2010;33(4):373–383.
14. Watkins S, Robel S, Kimbrough IF, Robert SM, Ellis-Davies G, Sontheimer H. Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells. Nat Commun. 2014;5:4196.
15. Cabezas R, Avila M, Gonzalez J, et al. Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease. Front Cell Neurosci. 2014;8:211.
16. Grossman SA, Ye X, Piantadosi S, et al.; NABTT CNS Consortium. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16(8):2443–2449.
17. Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16(23):5664–5678.
18. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.
19. Shah N, Liu Z, Tallman RM, et al. Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis. BMC Cancer. 2020;20(1):292.
20. Adkins CE, Mohammad AS, Terrell-Hall TB, et al. Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. Clin Exp Metastasis. 2016;33(4):373–383.

Funding

This research was supported by National Cancer Institute [grant numbers F99CA25376801] and P20GM121322 and supplement P20GM121322-03S1. Additional funding was provided by the Mylan Chair Endowment Fund and METAvivor.

Conflict of interest statement. S. Aulakh reports Consulting Fee or Advisory Board membership from TEMPUUS and Speakers’ Bureau from TEMPUUS. The other authors declare no conflicts of interest.

Authorship Statement. K.E.B., S.A.S., T.A.A., R.A.F., D.M.P., L.E.E., S.A., B.N.K., M.J.G., T.A.P., Y.M.C., and P.R.L. collaborated to write and review this article.
21. Mohammad AS, Adkins CE, Shah N, et al. Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer. *BMC Cancer*. 2018;18(1):1225.

22. Mittapalli RK, Adkins CE, Bohn KA, Mohammad AS, Lockman JA, Lockman PR. Quantitative fluorescence microscopy measures vascular pore size in primary and metastatic brain tumors. *Cancer Res*. 2017;77(2):238–246.

23. Millar BA, Purdie TG, Yeung I, et al. Assessing perfusion changes during whole brain irradiation for patients with cerebral metastases. *J Neurooncol*. 2005;71(3):281–286.

24. Ding B, Ling HW, Chen KM, Jiang H, Zhu YB. Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging. *Neuroradiology*. 2006;48(10):773–781.

25. Nakagawa H, Groothuis DR, Owens ES, Patlak CS, Pettigrew KD, Glasberg RR. Dexamethasone effects on vascular volume and tissue hemisphere in experimental RG-2 gliomas and adjacent brain. *J Neurooncol*. 1986;62(1):157–168.

26. Yano S, Shinohara H, Herbst RS, et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. *Cancer Res*. 2000;60(17):4959–4967.

27. Mittapalli RK, Manda VK, Bohn KA, Adkins CE, Lockman PR. Quantitative fluorescence microscopy provides high resolution imaging of passive diffusion and P-gp mediated efflux at the in vivo blood-brain barrier. *J Neurosci Methods*. 2013;219(1):188–195.

28. Adkins CE, Mittapalli RK, Manda VK, et al. P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. *Front Pharmacol*. 2013;4:136.

29. Adkins CE, Nounou MI, Hye T, et al. NKTR-102 efficacy versus irinotecan in a mouse model of brain metastases of breast cancer. *BMC Cancer*. 2015;15:685.

30. Bohn KA, Adkins CE, Nounou MI, Lockman PR. Inhibition of VEGF and angiopoietin-2 to reduce brain metastases of breast cancer burden. *Front Pharmacol*. 2017;8:193.

31. Mohammad AS, Griffith JI, Adkins CE, et al. Liposomal irinotecan accumulates in metastatic lesions, crosses the blood-tumor barrier (BTB), and prolongs survival in an experimental model of brain metastases of triple negative breast cancer. *Pharm Res*. 2018;35(2):31.

32. Nounou MI, Adkins CE, Rubinchik E, et al. Anti-cancer antibody trastuzumab-melanotransferrin conjugate (BT21111) for the treatment of metastatic HER2+ breast cancer tumors in the brain: an in vivo study. *Pharm Res*. 2016;33(12):2930–2942.

33. Shah N, Mohammad AS, Saralik P, et al. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. *Pharmacol Res*. 2018;132:47–68.

34. Terrell-Hall TB, Nounou MI, El-Amrawy F, Griffith JI, Lockman PR. Trastuzumab distribution in an in vivo and in vitro model of brain metastases of breast cancer. *OncoTarget*. 2017;8(48):83734–83744.

35. Perry DB, Ribot EJ, Chen Y, et al. In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. *Invest Radiol*. 2011;46(11):718–725.

36. Budde MD, Gold E, Jordan EK, Smith-Brown M, Frank JA. Phase contrast MRI is an early marker of micrometastatic breast cancer development in the rat brain. *NMR Biomed*. 2012;25(5):726–736.

37. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. *Am J Pathol*. 1992;141(5):1115–1124.

38. Palmieri D, Lockman PR, Thomas FC, et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. *Clin Cancer Res*. 2009;15(19):6148–6157.

39. Uehara H, Miyagawa T, Tjuvajev J, et al. Imaging experimental brain tumors with 1-aminocyclopyrene carboxylic acid and alpha-aminoisobutyric acid: comparison to fluoroexoglycoside and diethylenetriaminepentaacetic acid in morphologically defined tumor regions. *J Cereb Blood Flow Metab*. 1997;17(11):1239–1253.

40. Colombo T, Zucchetti M, D’Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. *J Pharmacol Exp Ther*. 1994;269(1):22–27.

41. Kemper EM, van Zandbergen AE, Cleypool C, et al. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. *Clin Cancer Res*. 2003;9(7):2849–2855.

42. Thomas FC, Taskar K, Rudraraju V, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. *Pharm Res*. 2009;26(11):2486–2494.

43. Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. *Pharm Res*. 2012;29(3):770–781.

44. Kim M, Kizilbash SH, Laramy JK, et al. Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine. *Pharm Res*. 2018;35(9):177.

45. Suh-JH, Kotecha R, Chao ST, Ahuwalia MS, Sahgal A, Chang EL. Current approaches to the management of brain metastases. *Nat Rev Clin Oncol*. 2020;17(5):279–299.

46. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. *Lancet Oncol*. 2002;3(1):53–57.

47. Barlesi F, Gervais R, Lena H, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFP-07-01). *Ann Oncol*. 2011;22(11):2466–2470.

48. Dinglin XX, Huang Y, Liu H, Zeng YD, Hou X, Chen LK. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. *J Neurooncol*. 2013;112(3):461–466.

49. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. *Ann Oncol*. 2001;12(1):59–67.

50. Cortes J, Rodriguez J, Aramendia JM, et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. *Oncology*. 2003;64(1):28–35.

51. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. *J Neurooncol*. 2013;112(3):461–466.

52. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. *Int J Radiat Oncol Biol Phys*. 2005;61(1):185–191.

53. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. *Anticancer Drugs*. 2007;18(1):23–28.

54. Zhang YK, Wang YJ, Gupta P, Chen ZS. Multidrug resistance proteins (MRPs) and cancer therapy. *AAPS J*. 2015;17(4):802–812.

55. Mansoori B, Mohammad A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. *Adv Pharm Bull*. 2017;7(3):339–348.

56. Mundt S, Greter M, Flügel A, Becher B. The CNS immune landscape from the viewpoint of a T cell. *Trends Neurosci*. 2019;42(10):667–679.
57. Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16(2):121–126.
58. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
59. Goldberg SB, Schalper KA, Gething SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655–663.
60. Tawbi HA, Forsyth PA, Alqazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;378(8):722–730.
61. Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M. Adjuvant cell therapy: past, present and future. Immunotherapy. 2017;9(2):183–196.
62. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells for brain tumors: lessons learned and road ahead. ImmunoL Rev. 2019;290(1):60–84.
63. Zhou S, Xie J, Huang Z, et al. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: mechanisms, advances, and challenges. Cancer Lett. 2021;502:166–179.
64. Ribatti D, Vacc A. Overview of angiogenesis during tumor growth. In: Figg WD, Folkman J, eds. Angiogenesis: An Integrative Approach from Science to Medicine. Boston, MA: Springer US; 2008:161–188.
65. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of brain metastases from NSCLC. Neurooncol Adv. 2020;3(1):e00149.
66. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1402–1419.
67. Restifo NP, Smyth MJ, Snyder A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer. 2016;16(2):121–126.
68. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
69. Goldberg SB, Schalper KA, Gething SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655–663.
70. Tawbi HA, Forsyth PA, Alqazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;378(8):722–730.
71. Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M. Adjuvant cell therapy: past, present and future. Immunotherapy. 2017;9(2):183–196.
72. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells for brain tumors: lessons learned and road ahead. ImmunoL Rev. 2019;290(1):60–84.
73. Zhou S, Xie J, Huang Z, et al. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: mechanisms, advances, and challenges. Cancer Lett. 2021;502:166–179.
74. Ribatti D, Vacc A. Overview of angiogenesis during tumor growth. In: Figg WD, Folkman J, eds. Angiogenesis: An Integrative Approach from Science to Medicine. Boston, MA: Springer US; 2008:161–188.
75. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of brain metastases from NSCLC. Neurooncol Adv. 2020;3(1):e00149.
95. Parkridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959–1972.

96. Sonali, Agrawal P, Singh RP, et al. Transfermin receptor-targeted vitamin E TPGS micelles for brain cancer therapy: preparation, characterization and brain distribution in rats. Drug Deliv. 2016;23(5):1788–1798.

97. Yin W, Zhao Y, Kang X, et al. BBB-penetrating codeelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR T790M mutation. Theranostics. 2020;10(4):6122–6135.

98. Wang X, Mao W, Wang Z, et al. Enhanced anti-brain metastasis from non-small cell lung cancer of osimertinib and doxorubicin co-delivery targeted nanocarrier. Int J Nanomedicine. 2020;15:5491–5501.

99. Wyatt EA, Davis ME. Method of establishing breast cancer brain metastases affecting brain uptake and efficacy of targeted, therapeutic nanoparticles. Bioeng Transl Med. 2019;4(1):30–37.

100. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol. 1997;138(4):877–889.

101. Guo Q, Zhu Q, Miao T, et al. LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases. J Control Release. 2019;303:117–129.

102. Li Y, Zheng X, Gong M, Zhang J. Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma. Oncotarget. 2016;7(48):79401–79407.

103. Li J, Di X, Zhang S, et al. Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. Colloids Surf B Biointerfaces. 2016;141:260–267.

104. Bhunia S, Vangala V, Bhattacharya D, et al. Large amino acid transporter 1 selective liposomes of DOPA functionalized amphiphile for combating glioblastoma. Mol Pharm. 2017;14(11):3834–3847.

105. Traxl A, Mairinger S, Filip T, et al. Inhibition of ABCB1 and ABCG2 at the mouse blood-brain barrier with marketed drugs to improve brain delivery of the model ABCB1/ABCG2 substrate [3H]Erlotinib. Mol Pharm. 2019;16(3):1282–1293.

106. Fellner S, Bauer B, Miller DS, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002;110(9):1309–1318.

107. Agarwal S, Sane R, Ohffest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCB2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther. 2011;336(1):223–233.